ABEO
Abeona Therapeutics Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-17
Figures on this page computed 2026-11-08 12:40 UTC
Last close
3.91USD
Market data, 2026-11-05
Except where said otherwise: 10-K for 2025, filed 2026-03-17
3.1xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001493152-26-010413
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-03-17
-84.5%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001493152-26-010413
- Reported in
- USD
- 10-K for 2025, filed 2026-03-17
- 10-K for 2025, filed 2026-03-17
- 10-K for 2025, filed 2026-03-17
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-17
- 10-Q for 2025, filed 2026-08-13
n/mNet marginnet income exceeds revenue
Net income exceeds revenue.
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001493152-26-010413
- Reported in
- USD
- 10-K for 2025, filed 2026-03-17
- 10-K for 2025, filed 2026-03-17
-1448.5%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001493152-26-010413
- Reported in
- USD
- 10-K for 2025, filed 2026-03-17
- 10-K for 2025, filed 2026-03-17
0.16Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001493152-26-010413
- Reported in
- USD
- 10-K for 2025, filed 2026-03-17
- 10-Q for 2025, filed 2026-08-13
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Margins is the furthest below its sector's middle: 0.32 against 0.41 on the market's range.
- Growth-10.3%50 of 100, at its sector
- Returns on capital-84.5%66 of 100, above its sector
- Margins73.7%32 of 100, below its sector
- Price3.1x50 of 100, above its sector
- Safety0.1660 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Five bars, one line
lens 7 of 9Each against its own average
5 of 5 readExcept where said otherwise: 10-K for 2025, filed 2026-03-17
- Sales1.64x
Its own average over 8 years, 3.6M.
- Profit-1.63x
Its own average over 10 years, -43.8M.
- Free cash flow1.74x
Its own average over 10 years, -48.4M.
- Debt1.04x
Its own average over 2 years, 24.0M.
- Price0.05x
Its own average over 11 years, 86. Market data, 2026-11-05
Profit is furthest from its own average, at -1.63 times.
Sales is 1.64 times its own 8-year average; Profit is -1.63 times its own 10-year average; Free cash flow is 1.74 times its own 10-year average; Debt is 1.04 times its own 2-year average; Price is 0.05 times its own 11-year average.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-03-17
Sales against its own 8-year average1.64
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001493152-26-010413
- Reported in
- USD
Profit against its own 10-year average-1.63
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001493152-26-010413
- Reported in
- USD
Free cash flow against its own 10-year average1.74
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001493152-26-010413
- Reported in
- USD
Debt against its own 2-year average1.04
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001493152-26-010413
- Reported in
- USD
Price against its own 11-year average0.05Market data, 2026-11-05
- Source
- market
- Taken on
- 2026-11-05
- Reported in
- USD